BridgeBio Pharma revenue and financials
$66.96Change from previous close: +1.24%Absolute change: +$0.82
In the fiscal year ended December 2025, BridgeBio Pharma reported revenue of $502.08M (+126.26% year over year). The net loss was $732.94M.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +126.26%
- 2025 vs 2024
- Net margin
- -146.0%
- 2024: -244.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -446 | -521 | -528 | -419 | -498 | -400 | -254 |
| Depreciation and amortization | 5.4 | 6.1 | 6.5 | 6.8 | 5.8 | 1.5 | 0.9 |
| Capital expenditure | -1.1 | -0.9 | -1.3 | -4.8 | -13.2 | -7.5 | -2.6 |
| Investing cash flow | -24.5 | 60.8 | 54.0 | 453 | -201 | — | — |
| Financing cash flow | 359 | 748 | 452 | -13.1 | 736 | — | — |
| Dividends paid | — | — | — | — | — | — | -1.0 |
| Share repurchases | -48.3 | 0.0 | 0.0 | 0.0 | -200 | -75.0 | — |
| Debt issued | 575 | 450 | 0.0 | 0.0 | — | — | — |
| Debt repaid | -459 | -473 | 0.0 | -20.5 | — | — | — |
| Net change in cash | -111 | 289 | -22.2 | 20.5 | 37.7 | — | — |
| Free cash flow | -447 | -522 | -529 | -424 | -511 | — | — |
| Levered free cash flow | -325 | -291 | -240 | -286 | -301 | — | — |